A recent preclinical study by U.S. Military HIV Research Program (MHRP) researchers showed that an experimental therapy combining a TLR7 agonist and two broadly neutralizing antibodies delayed viral rebound in SHIV-infected macaques after antiretroviral therapy (ART) interruption.
MHRP researchers recently published findings from a study comparing HIV gene and genome sequence analyses to help inform strategies to best estimate the timing of HIV infection.
In Kenya, the HIV epidemic among adolescents and young people between the ages of 10 and 24 is characterized by relatively high HIV incidence and sub-optimal treatment outcomes, including a high loss to follow-up, low adherence to treatment and low viral suppression.
The criteria described in this manuscript enabled rapid and efficient ART initiation across a diverse network of thirty participating clinical research sites in six countries.
MHRP, with Walter Reed Army Institute of Research (WRAIR) and the Henry M. Jackson Foundation (HJF), was selected by the National Institute of Allergy and Infectious Diseases (NIAID) at National Institute of Health as a Clinical Trial Unit (CTU) for their HIV research networks for the next seven years.